

Long QT Syndrome

Prevenzione Morte Improvvisa secondo LG ACC- AHA-ESC 2006

Recommendations

Class I

- Lifestyle modification** is recommended for patients with an LQTS diagnosis (clinical and/or molecular). (*Level of Evidence: B*)
- Beta blockers** are recommended for patients with an LQTS clinical diagnosis (i.e., in the presence of prolonged QT interval). (*Level of Evidence: B*)
- Implantation of an ICD along with use of beta blockers is recommended for LQTS patients with previous cardiac arrest** and who have reasonable expectation of survival with a good functional status for more than 1 y. (*Level of Evidence: A*)



Class IIa

- Beta blockers can be effective to reduce SCD in patients with a molecular LQTS analysis and normal QT interval. (*Level of Evidence: B*)
- Implantation of an ICD with continued use of beta blockers can be effective to reduce SCD in LQTS patients experiencing syncope and/or VT** while receiving beta blockers and who have reasonable expectation of survival with a good functional status for more than 1 y. (*Level of Evidence: B*)

Class IIb

- Left cardiac sympathetic neural denervation may be considered for LQTS patients with syncope, torsades de pointes, or cardiac arrest while receiving beta blockers. (*Level of Evidence: B*)
- Implantation of an ICD with the use of beta blockers may be considered for prophylaxis of SCD for patients in categories possibly associated with higher risk of cardiac arrest such as LQT2 and LQT3** and who have reasonable expectation of survival with a good functional status for more than 1 y. (*Level of Evidence: B*)

	<i>I</i>	<i>IIA</i>	<i>IIB</i>
<i>Prevenzione primaria</i>	Beta blockers are recommended for patients with an LQTS clinical diagnosis (i.e., in the presence of prolonged QT interval) . (<i>Level of Evidence: B</i>)	Beta blockers can be effective to reduce SCD in patients with a molecular LQTS analysis and normal QT interval . (<i>Level of Evidence: B</i>)	Implantation of an ICD with the use of beta blockers may be considered for prophylaxis of SCD for patients in categories possibly associated with higher risk of cardiac arrest such as LQT2 and LQT3 and who have reasonable expectation of survival with a good functional status for more than 1 y. (<i>Level of Evidence: B</i>)
<i>Prevenzione Secondaria</i>	Implantation of an ICD along with use of beta blockers is recommended for LQTS patients with previous cardiac arrest and who have reasonable expectation of survival with a good functional status for more than 1 y. (<i>Level of Evidence: A</i>)	Implantation of an ICD with continued use of beta blockers can be effective to reduce SCD in LQTS patients experiencing syncope and/or VT while receiving beta blockers and who have reasonable expectation of survival with a good functional status for more than 1 y. (<i>Level of Evidence: B</i>)	



Causes and Risk Factors

The LQTS is an inherited disease characterized by prolonged ventricular repolarization (QT interval) and by ventricular tachyarrhythmias that may manifest as syncopal events. Cardiac arrhythmias are often elicited by stress and emotion, although in some cases they may also occur at rest or during sleep. Two patterns of inheritance have been identified: the more common autosomal dominant **Romano-Ward** and Timothy syndromes and the much rarer autosomal recessive cases. The latter are usually more severe, often but not always involving consanguineous marriages, and are often associated with congenital deafness (the **Jervell Lange-Nielsen** syndrome). Mutations in 8 genes have been identified: 7 of them encode cardiac ion channel subunits and 1 encodes an anchoring protein that has been implicated in controlling ion channel targeting specific membrane sites. The distinguishing features of some of the genetic variants of the disease have been identified and incorporated in risk stratification algorithms.

Risk Stratification

Even before the identification of the genetic subtypes, QT interval duration was identified as the strongest predictor of risk for cardiac events (syncope, SCD) in LQTS, and it remains so. A normal QT interval in an ungenotyped family member portends a good prognosis. A **QTc exceeding 500 ms (corresponding to the upper QTc quartile among affected genotyped individuals) identifies patients with the highest risk** of becoming symptomatic by age 40. Patients with the Jervell Lange-Nielsen and other homozygous syndromes and patients with LQTS associated with syndactyly are at higher risk. A family history of SCD has not proved to be a risk factor for SCD.

Genetic testing is often useful in probands with a clinical diagnosis of LQTS to provide more accurate risk stratification and to guide therapeutic strategies.

Symptoms in LQTS range from SCD to syncope and near syncope. Patients resuscitated from SCD have an especially ominous prognosis, with a relative risk of 12.9 of experiencing another cardiac arrest. In addition, affected patients may be identified because of QT prolongation detected incidentally or because they are relatives of affected individuals and are found to be mutation carriers in genetic screening; prognosis in such family members tends to be better than that for the proband. **Risk is increased during the immediate postpartum period**. It has been shown that the interplay between genetic defect, QT duration, and gender may provide an algorithm for risk stratification. Patients with the highest risk of becoming symptomatic are LQT1 and LQT2 patients with a QTc greater than 500 ms and males with LQT3 irrespective of QT interval duration. LQT3 patients may represent a group at higher risk. Among LQT2 patients, those with a mutation resulting in a change in the pore region of the protein appear to be at higher risk of cardiac events than are those with mutations in other regions of the gene. **Beta blockers are highly effective in LQT1, whereas they offer incomplete protection in LQT2 and LQT3**.

Ventricular Arrhythmias

Syncope in LQTS patients is usually attributed to severe ventricular arrhythmias (although other causes can occur). Syncopal events are usually associated with stress, emotion, or exercise; however, gene-specific triggers for cardiac events have been identified in the 3 most common genetic variants of the disease. Individuals affected by the **LQT1** form of the disease (mutations in the *KCNQ1* or *KvLQT1* gene encoding the ion channel that conducts the potassium current IKs) are **more susceptible to cardiac events occurring during exercise** and particularly during swimming. **LQT2** patients harbor mutations in the *KCNH2* (or *HERG*) gene encoding the channel conducting the potassium current IKr are susceptible

to cardiac events occurring during rest or emotion, and characteristically with acoustic stimuli . Finally, LQT3 patients carrying mutations in the SCN5A gene encoding the cardiac sodium channel are susceptible to cardiac events occurring at rest and during sleep .

A description of the long QT subtypes is given in Table

Long QT Syndrome Subtypes

Variant	Gene	Chromosome	Function	evento	
LQT1	KCNQ1	11p15.5	IKs	alpha subunit	ACR da sforzo
LQT2	KCNH2	7q35-35	IKr	alpha subunit	ACR riposo, stress rumore
LQT3	SCN5A	3p21-23	INa	alpha subunit	ACR nel sonno
LQT4	ANK2	4q25-2		Targeting protein	
LQT5	KCNE1	21p22.1-22-2		IKs beta subunit	
LQT6	KCNE2	21p22.1-22-2		IKr beta subunit	
LQT7	KCNJ2	17p23.1-24.2		IK1	
LQT8	CACNA1C	12p13.3		ICa alpha subunit	
JLN1	KCNQ1	11p15.5	IK	s alpha subunit	
JLN2	KCNE1	21p22.1-22-2		IKr beta subunit	

The mean age for first manifestation of the disease is 12 y, but there is a wide range from the first year of life to as late as the fifth through sixth decades. Documentation of the arrhythmia during cardiac events is relatively uncommon in LQTS: when arrhythmias are recorded, the characteristic polymorphic VT, “torsades de pointes,” is identified ; SCD may be the first manifestation of the disease.

Lifestyle Changes

It is recommended that all patients affected by LQTS avoid competitive sports activity . For LQT1 patients, swimming should be specifically limited or performed under supervision. LQT2 patients should avoid exposure to acoustic stimuli especially during sleep (avoidance of telephone and alarm clock on the night stand). All patients with LQTS should avoid drugs known to prolong the QT interval and those that deplete potassium and magnesium.

Tabella 4. Farmaci potenzialmente a rischio di prolungare il tratto QT.

Farmaci cardiovascolari	Farmaci SNC	Farmaci respiratorio	Farmaci antivirali	Farmaci decongestionanti nasali
Amiodarone	Olanzapina	Salbutamolo	Amantidina	antistaminici
Chinidina	Paroxetina	Salmeterolo	Foscarnet	Fenilefrina
Disopiramide	Quetiapina	Terbutalina	Farmaci antiparassitari	Fenilpropanolamina
Dobutamina	Risperidone		Cloroquina	Pseudoefedrina
Dopamina	Sertindolo	Farmaci antibatterici	Meflochina	Terfenadina
Efedrina	Sertralina	Azitromicina	Pentamidina	Altri farmaci
Epinefrina	Tioridazina	Ciprofloxacina		Alfuzosina
Flecainide	Tizanidina	Claritromicina	Farmaci antimicotici	Octreotide
Ibutilide	Trimipramina	Eritromicina	Fluconazolo	Sibutramina
Indapamide	Venlafaxina	Levofloxacina	Itraconazolo	Tacrolimus
Isradipina	Farmaci GI	Moxifloxacina	Ketoconazolo	Tamoxifene
Midodrina	Dolasetron	Ofloxacina	Voriconazolo	Vardenafil
Norepinefrina	Domperidone	Cotrimossazolo		
Sotalolo	Granisetron			
	Ondansetron			
	Nortriptilina			